NCT03384914 2026-03-06Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Active not recruiting119 enrolled
NCT03516279 2026-03-02Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual DiseaseEastern Cooperative Oncology GroupPhase 2 Active not recruiting40 enrolled